These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1555 related items for PubMed ID: 29096949

  • 1. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.
    Colombel JF, Panaccione R, Bossuyt P, Lukas M, Baert F, Vaňásek T, Danalioglu A, Novacek G, Armuzzi A, Hébuterne X, Travis S, Danese S, Reinisch W, Sandborn WJ, Rutgeerts P, Hommes D, Schreiber S, Neimark E, Huang B, Zhou Q, Mendez P, Petersson J, Wallace K, Robinson AM, Thakkar RB, D'Haens G.
    Lancet; 2017 Dec 23; 390(10114):2779-2789. PubMed ID: 29096949
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial.
    van Linschoten RCA, Jansen FM, Pauwels RWM, Smits LJT, Atsma F, Kievit W, de Jong DJ, de Vries AC, Boekema PJ, West RL, Bodelier AGL, Gisbertz IAM, Wolfhagen FHJ, Römkens TEH, Lutgens MWMD, van Bodegraven AA, Oldenburg B, Pierik MJ, Russel MGVM, de Boer NK, Mallant-Hent RC, Ter Borg PCJ, van der Meulen-de Jong AE, Jansen JM, Jansen SV, Tan ACITL, van der Woude CJ, Hoentjen F, LADI study group and the Dutch Initiative on Crohn and Colitis.
    Lancet Gastroenterol Hepatol; 2023 Apr 23; 8(4):343-355. PubMed ID: 36736339
    [Abstract] [Full Text] [Related]

  • 5. Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.
    Feagan BG, Panés J, Ferrante M, Kaser A, D'Haens GR, Sandborn WJ, Louis E, Neurath MF, Franchimont D, Dewit O, Seidler U, Kim KJ, Selinger C, Padula SJ, Herichova I, Robinson AM, Wallace K, Zhao J, Minocha M, Othman AA, Soaita A, Visvanathan S, Hall DB, Böcher WO.
    Lancet Gastroenterol Hepatol; 2018 Oct 23; 3(10):671-680. PubMed ID: 30056030
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Adalimumab for maintenance of remission in Crohn's disease.
    Townsend CM, Nguyen TM, Cepek J, Abbass M, Parker CE, MacDonald JK, Khanna R, Jairath V, Feagan BG.
    Cochrane Database Syst Rev; 2020 May 16; 5(5):CD012877. PubMed ID: 32413933
    [Abstract] [Full Text] [Related]

  • 9. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
    Feagan BG, Sandborn WJ, D'Haens G, Panés J, Kaser A, Ferrante M, Louis E, Franchimont D, Dewit O, Seidler U, Kim KJ, Neurath MF, Schreiber S, Scholl P, Pamulapati C, Lalovic B, Visvanathan S, Padula SJ, Herichova I, Soaita A, Hall DB, Böcher WO.
    Lancet; 2017 Apr 29; 389(10080):1699-1709. PubMed ID: 28411872
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.
    Kennedy NA, Heap GA, Green HD, Hamilton B, Bewshea C, Walker GJ, Thomas A, Nice R, Perry MH, Bouri S, Chanchlani N, Heerasing NM, Hendy P, Lin S, Gaya DR, Cummings JRF, Selinger CP, Lees CW, Hart AL, Parkes M, Sebastian S, Mansfield JC, Irving PM, Lindsay J, Russell RK, McDonald TJ, McGovern D, Goodhand JR, Ahmad T, UK Inflammatory Bowel Disease Pharmacogenetics Study Group.
    Lancet Gastroenterol Hepatol; 2019 May 29; 4(5):341-353. PubMed ID: 30824404
    [Abstract] [Full Text] [Related]

  • 12. Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease.
    Ungaro RC, Yzet C, Bossuyt P, Baert FJ, Vanasek T, D'Haens GR, Joustra VW, Panaccione R, Novacek G, Reinisch W, Armuzzi A, Golovchenko O, Prymak O, Goldis A, Travis SP, Hébuterne X, Ferrante M, Rogler G, Fumery M, Danese S, Rydzewska G, Pariente B, Hertervig E, Stanciu C, Serrero M, Diculescu M, Peyrin-Biroulet L, Laharie D, Wright JP, Gomollón F, Gubonina I, Schreiber S, Motoya S, Hellström PM, Halfvarson J, Butler JW, Petersson J, Petralia F, Colombel JF.
    Gastroenterology; 2020 Jul 29; 159(1):139-147. PubMed ID: 32224129
    [Abstract] [Full Text] [Related]

  • 13. Validation of endoscopic activity scores in patients with Crohn's disease based on a post hoc analysis of data from SONIC.
    Ferrante M, Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens GR, van der Woude CJ, Danese S, Diamond RH, Oortwijn AF, Tang KL, Miller M, Cornillie F, Rutgeerts PJ, International Organization for the Study of Inflammatory Bowel Diseases.
    Gastroenterology; 2013 Nov 29; 145(5):978-986.e5. PubMed ID: 23954314
    [Abstract] [Full Text] [Related]

  • 14. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial.
    Noor NM, Lee JC, Bond S, Dowling F, Brezina B, Patel KV, Ahmad T, Banim PJ, Berrill JW, Cooney R, De La Revilla Negro J, de Silva S, Din S, Durai D, Gordon JN, Irving PM, Johnson M, Kent AJ, Kok KB, Moran GW, Mowat C, Patel P, Probert CS, Raine T, Saich R, Seward A, Sharpstone D, Smith MA, Subramanian S, Upponi SS, Wiles A, Williams HRT, van den Brink GR, Vermeire S, Jairath V, D'Haens GR, McKinney EF, Lyons PA, Lindsay JO, Kennedy NA, Smith KGC, Parkes M, PROFILE Study Group.
    Lancet Gastroenterol Hepatol; 2024 May 29; 9(5):415-427. PubMed ID: 38402895
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Low dose naltrexone for induction of remission in Crohn's disease.
    Segal D, Macdonald JK, Chande N.
    Cochrane Database Syst Rev; 2014 Feb 21; (2):CD010410. PubMed ID: 24558033
    [Abstract] [Full Text] [Related]

  • 18. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
    Colombel JF, Sandborn WJ, Rutgeerts P, Kamm MA, Yu AP, Wu EQ, Pollack PF, Lomax KG, Chao J, Mulani PM.
    Am J Gastroenterol; 2009 May 21; 104(5):1170-9. PubMed ID: 19352339
    [Abstract] [Full Text] [Related]

  • 19. Prospective study of an adalimumab combined with partial enteral nutrition in the induction period of Crohn's disease.
    Zhou S, Huang Z, Hou W, Lin Y, Yu J.
    Inflamm Res; 2024 Feb 21; 73(2):199-209. PubMed ID: 38168701
    [Abstract] [Full Text] [Related]

  • 20. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.
    Sands BE, Irving PM, Hoops T, Izanec JL, Gao LL, Gasink C, Greenspan A, Allez M, Danese S, Hanauer SB, Jairath V, Kuehbacher T, Lewis JD, Loftus EV, Mihaly E, Panaccione R, Scherl E, Shchukina OB, Sandborn WJ, SEAVUE Study Group.
    Lancet; 2022 Jun 11; 399(10342):2200-2211. PubMed ID: 35691323
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 78.